Cargando…

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer

INTRODUCTION: Mitochondria are a significant target of lonidamine (LND). However, its limited solubility and inability to specifically target mitochondria, LND can lead to hepatic toxicity and has shown only modest anticancer activity. The objective of this study is to establish a glutathione progra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhongjie, Qin, Yanru, Wang, Xueyuan, Zhang, Tianyu, Hu, Yixue, Wang, Dongna, Zhang, Liefeng, Zhu, Yongqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378575/ https://www.ncbi.nlm.nih.gov/pubmed/37520302 http://dx.doi.org/10.2147/IJN.S413217

Ejemplares similares

Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis
por: Cheng, Gang, et al.
Publicado: (2019)

Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles
por: Li, Huizhen, et al.
Publicado: (2022)

Mitochondrial Targeting and pH-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance
por: Chen, Enping, et al.
Publicado: (2021)

Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine
por: Bhutia, Yangzom D., et al.
Publicado: (2016)

In Vitro Effect of Mitochondria-Targeted Triphenylphosphonium-Based Compounds (Honokiol, Lonidamine, and Atovaquone) on the Platelet Function and Cytotoxic Activity
por: Montecino-Garrido, Héctor, et al.
Publicado: (2022)

Ru(III) Complexes with Lonidamine-Modified Ligands
por: Shutkov, Ilya A., et al.
Publicado: (2021)

Phase II study of lonidamine in metastatic breast cancer.
por: Pronzato, P., et al.
Publicado: (1989)

Inhibition of the recovery from potentially lethal damage by lonidamine.
por: Hahn, G. M., et al.
Publicado: (1984)

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
por: Guo, Lili, et al.
Publicado: (2016)

Glutathione and mitochondria
por: Ribas, Vicent, et al.
Publicado: (2014)

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment
por: Chen, Tianyu, et al.
Publicado: (2022)

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment
por: Huang, Yaxin, et al.
Publicado: (2020)

Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases
por: Chen, Chen, et al.
Publicado: (2022)

Effect of lonidamine derivatives on the inhibition of transformed cell area expansion
por: Aoyama, Megumi, et al.
Publicado: (2023)

New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents
por: Shutkov, Ilya A., et al.
Publicado: (2023)

Discovering a Reversible Male Contraceptive Agent Derived from Lonidamine
por: Gong, Shengnan, et al.
Publicado: (2023)

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
por: Silvestrini, B., et al.
Publicado: (1983)

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.
por: Citro, G., et al.
Publicado: (1991)

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin
por: Nath, Kavindra, et al.
Publicado: (2018)

Phase II study of lonidamine in non-small cell lung cancer: final report.
por: Kokron, O., et al.
Publicado: (1990)

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
por: Mansi, J. L., et al.
Publicado: (1991)

In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosussensu stricto and Echinococcus multilocularis
por: Xin, Qi, et al.
Publicado: (2020)

The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease
por: Sundar, Shirin V., et al.
Publicado: (2022)

Antitumor Actions of Intratumoral Delivery of Membrane-Fused Mitochondria in a Mouse Model of Triple-Negative Breast Cancers
por: Chang, Jui-Chih, et al.
Publicado: (2020)

In vivo AAV delivery of glutathione reductase gene attenuates anti-aging gene klotho deficiency-induced kidney damage
por: Gao, Diansa, et al.
Publicado: (2020)

Lonidamine and domperidone inhibit expansion of transformed cell areas by modulating motility of surrounding nontransformed cells
por: Aoyama, Megumi, et al.
Publicado: (2022)

pH-dependent structural characteristics of lonidamine: (1)H and (13)C NMR study
por: Gupta, Pradeep Kumar, et al.
Publicado: (2023)

Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma
por: Ma, Chenjun, et al.
Publicado: (2021)

Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.
por: De Cesare, M., et al.
Publicado: (1998)

Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
por: Cervantes-Madrid, Diana, et al.
Publicado: (2015)

KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling
por: Wen, Tiantian, et al.
Publicado: (2023)

Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
por: Fang, Hanyi, et al.
Publicado: (2021)

Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
por: Milane, Lara, et al.
Publicado: (2011)

Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity
por: Cai, Jing, et al.
Publicado: (2020)

LC-MS based stability-indicating method for studying the degradation of lonidamine under physical and chemical stress conditions
por: Rochani, Ankit Kanaiyalal, et al.
Publicado: (2020)

Cu(I) and Cu(II) Complexes Based on Lonidamine-Conjugated Ligands Designed to Promote Synergistic Antitumor Effects
por: Del Bello, Fabio, et al.
Publicado: (2022)

Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data
por: Xing, Kaiyuan, et al.
Publicado: (2023)

The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes
por: Davidescu, Magdalena, et al.
Publicado: (2015)

Activation of the eIF2α/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis
por: Bai, Xupeng, et al.
Publicado: (2021)

Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer
por: Khanna, Vidhi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8sedit64879kst7icsa7mu38a2